Why the study?
Does bretylium tosylate improve ventricular refractoriness inhomogeneity and ventricular fibrillation threshold in a canine model of quinidine-induced long QT interval?
Population
3 anaesthetised open chest dogs with quinidine-induced long QT interval
Comparison
Bretylium tosylate 6 mg/kg injected… vs Pre-bretylium baseline
Design
Preclinical
Follow-up
30 to 60 min after injection
Authors
Loading...
No immediate clinical adoption warranted; leaves open bretylium's role in quinidine-induced long QT pending human validation.
Does bretylium tosylate improve ventricular refractoriness inhomogeneity and ventricular fibrillation threshold in a canine model of quinidine-induced long QT interval?
In a canine model of quinidine-induced long QT interval, bretylium tosylate decreased temporal dispersion of refractoriness and increased the ventricular fibrillation threshold.
Inoue et al. (1985) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: